Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/43214
Conference/Presentation Title: Preliminary safety data from patients (pts) with relapsed/refractory (R/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417. [Hematological Oncology]
Authors: Cheah C.Y.;Verner E.;Tam C.S.;Hilger J.;Gao Y.;Huang J.;Simpson D.;Opat S. 
Institution: (Cheah) Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine, Nedlands; Medical School, University of Western Australia, Nedlands, Australia
(Verner) Concord Repatriation General Hospital, Concord; University of Sydney, Haematology, Sydney, Australia
(Tam) Peter MacCallum Cancer Centre, Melbourne; University of Melbourne, St Vincent's Hospital, Parkville, Australia
(Hilger, Gao, Huang, Simpson) BeiGene (Beijing) Co.,Ltd., Beijing, China
(Opat) Monash Health and Monash University, Haematology, Clayton, Australia
Presentation/Conference Date: 25-Jun-2021
Copyright year: 2021
Publisher: John Wiley and Sons Ltd
Conference location: Netherlands
Publication information: Hematological Oncology. Conference: 16th International Conference on Malignant Lymphoma. Virtual. 39 (SUPPL 2) (pp 457-458), 2021. Date of Publication: June 2021.
Journal: Hematological Oncology
Abstract: Background: BCL2, a key regulator of the apoptotic pathway, is aberrantly expressed in many hematologic malignancies. Treatment with BCL2 inhibitor venetoclax can be limited by common mild gastrointestinal toxicities, neutropenia, and emergence of BCL2 mutations. BGB-11417 was developed as a potent and highly selective inhibitor of BCL2 and has shown antitumor activity superior to venetoclax in acute lymphoblastic leukemia, mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL) xenograft models. BGB-11417 has a favorable pharmacokinetic profile with low plasma clearance in rodents and dogs. Toxicology study results have shown a broad safety window and excellent safety profile. Method(s): BGB-11417-101 is a first-in-human phase 1/1b study (dose escalation and safety expansion) to determine safety, tolerability, maximum tolerated dose (MTD), and recommended phase 2 dose of BGB-11417 in pts with R/R B-cell malignancies (NCT04277637). For dose escalation, pts were enrolled in 1 of 5 oral BGB-11417 dose levels (40, 80, 160, 320, or 640 mg once daily) and received weekly or daily dose ramp-up; pts with non-Hodgkin lymphomas (NHLs) received 2-day ramp-up (day 1, 25% of intended dose; day 2, 50%) before reaching the intended daily dose (day 3+, 100%). Adverse events (AEs) were reported per CTCAE v5.0. A Bayesian logistic regression model was used to evaluate dose-limiting toxicities (DLTs; during ramp-up through day 21 at intended daily dose) and determine the MTD. The first dose-escalation cohort allowed pts with R/R follicular lymphoma (FL), marginal zone lymphoma (MZL), DLBCL, or transformed NHL. Result(s): As of 01/01/2021, 7 pts with R/R NHL had been treated. A cohort of R/R chronic lymphocytic leukemia (CLL) had just opened with 2 pts treated. Only data from the NHL pts are reported (5 DLBCL, 1 FL, and 1 MZL), with median follow-up of 2.9 mo (range, 1.7-7.7). The 40-mg (n = 3) and 80-mg (n = 4) dose cohorts are complete with no DLTs. The 160-mg dose cohort is underway. AEs occurring in >1 pt are listed in Table 1. Four pts discontinued (disease progression [n = 3; 2 at 40 mg, 1 at 80 mg] or lack of efficacy [n = 1 at 40 mg]), and 3 pts remain on treatment. No pt discontinued from AEs, and no instances of laboratory or clinical tumor lysis syndrome were observed. Conclusion/Summary: These early phase 1 results suggest that BGB-11417 is tolerable in pts with R/R NHL at dose levels tested. Preliminary activity in this pt population will be assessed with increased enrollment and follow-up. Enrollment of pts with R/R CLL is underway, and decreases in lymphocyte count have been seen at the initial ramp-up dose of 1 mg. Evaluation of pts with MCL and Waldenstrom macroglobulinemia, and the combination of BGB-11417 and Bruton tyrosine kinase inhibitor zanubrutinib, is planned for future cohorts.
DOI: http://dx.doi.org/10.1002/hon.2881
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/43214
Type: Conference Abstract
Subjects: cancer patient
cancer recurrence
cancer resistance
chronic lymphatic leukemia
clinical evaluation
diffuse large B cell lymphoma
dog
drug safety
drug toxicity
follicular lymphoma
lymphocyte count
mantle cell lymphoma
marginal zone lymphoma
maximum tolerated dose
molecularly targeted therapy
pharmacokinetics
phase 1 clinical trial
phase 2 clinical trial
plasma clearance
plasmacytoma
rodent
therapeutic index
toxicology
tumor lysis syndrome
Waldenstroem macroglobulinemia
endogenous compound
protein bcl 2
zanubrutinib
Type of Clinical Study or Trial: Observational study (cohort, case-control, cross sectional or survey)
Appears in Collections:Conferences

Show full item record

Page view(s)

40
checked on Mar 15, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.